MedTrace Logo

Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas

NCT04656730 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2023-09-22

No results posted yet for this study

Summary

Study to asess the effects of Iberogast® (STW5) and Iberogast® N (STW5-II) in intestinal gas transit and abdominal symptoms of patients suffering from irritable bowel syndrome or functional dyspepsia.

Conditions

  • Irritable Bowel Syndrome
  • Functional Dyspepsia

Interventions

DRUG

Iberogast® and Iberogast® N

Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days,

Sponsors & Collaborators

  • Bayer Hispania, S.L

    collaborator UNKNOWN

  • Hospital Vall d'Hebron

    lead OTHER

Principal Investigators

  • JORDI SERRA, MD, PhD · Germans Trias i Pujol Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-03
Primary Completion
2023-01-31
Completion
2023-01-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04656730 on ClinicalTrials.gov